

The National Academies of
SCIENCES • ENGINEERING • MEDICINE

Committee on Addressing Evidence Gaps in Clinical Prevention
Meeting 4, Part 2 | March 16, 2021
Agenda

[You may access the Zoom meeting here.](#)

11:00 am ET	Welcome and introduction, brief recap of previous session
	Tracy Lieu, MD, MPH , Chair, Committee on Addressing Evidence Gaps in Clinical Prevention; Director, Kaiser Permanente Northern California Division of Research
11:10 am ET	Perspectives on addressing evidence gaps: The CDC Community Guide
	Amy Lansky, PhD, MPH , Director, Centers for Disease Control and Prevention (CDC) Community Guide
11:20 am ET	Perspectives on addressing evidence gaps: Funders
	Michael S. Lauer, MD , Deputy Director for Extramural Research at the National Institutes of Health (NIH) Harold (Hal) Sox, MD , Director, Peer Review, Patient-Centered Outcomes Research Institute (PCORI) David Atkins, MD, MPH , Director of Health Services Research & Development, U.S. Department of Veterans Affairs (VA)
11:50 am ET	Moderated Discussion <i>The moderator will facilitate a discussion between the first four speakers and committee. Discussion questions may include:</i> <ul style="list-style-type: none">• <i>To what extent and how do sponsors prioritize evidence gaps?</i>• <i>What are some examples of successful partnerships you have had with other organizations or institutions to address evidence gaps?</i>
12:10 pm ET	Break

12:15 pm ET	Case example: Autism screening “I” statement impact on the research community
	<p>Michael Silverstein, MD, MPH, Member, US Preventive Services Task Force; Professor of Pediatrics, Director of the Division of General Academic Pediatrics, and Vice Chair of Research for the Department of Pediatrics at Boston University School of Medicine (BUSM)</p> <p>Ann E. Wagner, PhD, Department of Health and Human Services (HHS) National Autism Coordinator, Office of NIMH Director, National Institute of Mental Health</p> <p>Sarabeth Broder-Fingert, MD, MPH, Associate Professor of Pediatrics, BUSM; Co-Director, Innovation in Autism Disparities, Inclusion, Outreach, and Transition Services Lab, Boston University</p>
12:30 pm ET	<p>Moderated Discussion</p> <p><i>The moderator will facilitate a discussion between the speakers and audience. Possible discussion questions may include:</i></p> <ul style="list-style-type: none"> • <i>How did you become aware of evidence gaps identified by the USPSTF recommendations? Why have they influenced your research?</i> • <i>How specifically did they affect or drive your research topics?</i> • <i>Have TF recommendations (evidence gaps) appeared to affect you or your colleagues’ focus of research? Have they offered new insight about research directions or do they serve as a reminder of what the research community already knows?</i> • <i>Has the level of detail in evidence gaps been helpful in guiding your research? What changes would be useful in terms of providing guidance to researchers?</i>
1:05 pm ET	Reflections on a taxonomy of evidence gaps and research to close them
	<p>Ned Calonge, MD, MPH, President and CEO, Colorado Trust; Associate Professor of Family Medicine, Colorado School of Medicine, and Associate Professor of Epidemiology, Colorado School of Public Health, University of Colorado Denver</p> <p>Alan I. Leshner, PhD, CEO Emeritus, American Association for the Advancement of Science (AAAS) and Executive Publisher, <i>Science Magazine</i> (2001–2015); Former Director, National Institute on Drug Abuse (NIDA) (1994–2001); Former Deputy Director and Acting Director, NIMH (1988–1994)</p>
2 pm	Adjourn